title: Is it time to abandon warfarin and embrace oral direct thrombin inhibitors to prevent stroke in patients with atrial fibrillation?
authors.forename: Rudy J
authors.initials: RJ
authors.lastname: Rahme
authors.forename: Richard
authors.initials: R
authors.lastname: Bernstein
authors.forename: H Hunt
authors.initials: HH
authors.lastname: Batjer
authors.forename: Bernard R
authors.initials: BR
authors.lastname: Bendok
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000627:therapeutic use*; D000991:Antithrombins / Q000008:administration & dosage*; D001281:Atrial Fibrillation / Q000150:complications; D001562:Benzimidazoles / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D000069604:Dabigatran; D006801:Humans; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*; D014859:Warfarin / Q000627:therapeutic use*; D015091:beta-Alanine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D000991:Antithrombins; D001562:Benzimidazoles; D015091:beta-Alanine; D014859:Warfarin; D000069604:Dabigatran